Manipulating immunodominance in influenza HA
Manipulating immunodominance in influenza HA
批准号:
8720678
负责人:
PHILIP R DORMITZER
金额:
$51.3万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Activities of Daily LivingAdjuvantAffinityAntibodiesAntigensB cell repertoireBindingChildCompetitive BindingComplexDiseaseDrug FormulationsEngineeringEpitope MappingEpitopesEscape MutantExposure toGerm LinesHemagglutininImmune responseImmune systemImmunizationInfectionInfluenzaInfluenza HemagglutininInfluenza vaccinationInstructionLearningLibrariesMapsMasksMemory B-LymphocyteMonoclonal AntibodiesMusPathway interactionsPlasmablastRaceRecording of previous eventsResolutionSpecificityStructureTechniquesTestingTimeVaccine AntigenVaccinesVirusWorkdesignhigh throughput screeninghuman subjectimprovedinfluenza virus vaccineinsightiterative designneutralizing antibodypandemic diseasepathogenresponsestem
中文摘要
每种流感血凝素(HA)都是保守的和毒株特异性表位的镶嵌体,其中一些表位是
被中和抗体识别。优先激发中和抗体的流感疫苗
识别保守表位的抗体将比现在使用的抗体具有更广泛的保护性。了解如何
受试者的暴露史、流感疫苗抗原的差异和佐剂的添加使受试者的免疫应答产生偏差。
针对不同HA表位的免疫应答将使我们能够设计最佳疫苗。以下三
将对假设进行检验。(1]非复制型流感疫苗和流感疫苗诱导的B细胞库
感染在多克隆活化程度和中和宽度方面不同。所引出的剧目,
有佐剂的和无佐剂的疫苗不同,因为佐剂扩大了识别表位的范围。(二)
广泛反应性抗体,包括识别异亚型茎表位的抗体,在
由于多种HA的应答扩大,
刺激。(3)针对所需表位的抗体的有效诱导需要:
有利的种系抗体和(B)达到所需最终特异性的亲和力成熟途径。有
优选的种系前体和靶向特定表位的抗体的成熟途径。
假设1和2将通过绘制人类受试者的所有库识别的表位来检验
具有不同的流感感染暴露史和/或用佐剂或非佐剂免疫
疫苗。我们将寻求广泛中和抗体(我们想要引发的抗体)来了解它们的种系
前体和成熟途径。我们还将绘制结合HA的全系列抗体的表位
以确定体液免疫系统“看到了什么”。“从这一映射中获得的见解将用于
合理设计将通过抗原的迭代循环优化的上级HA免疫原
工程化、小鼠免疫、库分析和抗原重新设计。抗原设计技术将
包括选择性表位呈递、表位掩蔽和生殖系抗体靶向,随后进行引导
亲和力成熟本工作揭示的抗原设计原则可应用于保护性免疫
需要疫苗的多种病原体的决定因素。
英文摘要
Each influenza hemagglutinin (HA) is a mosaic of conserved and strain-specific epitopes, some of which are
recognized by neutralizing antibodies. An influenza vaccine that preferentially elicits neutralizing antibodies
that recognize conserved epitopes will be more broadly protective than those now in use. Understanding how
the exposure history of subjects, differences in influenza vaccine antigens, and the addition of adjuvants bias the
immune response towards different HA epitopes will enable us to design optimal vaccines. The following three
hypotheses will be tested. (1] The B-cell repertoires elicited by non-replicating influenza vaccines and by
infection differ in degree of polyclonal activation and breadth of neutralization. The repertoires elicited by
adjuvanted and non-adjuvanted vaccines differ because adjuvant broadens the range of recognized epitopes. (2]
Broadly reactive antibodies, including those recognizing the heterosubtypic stem epitope, are less frequent after
true primary than after secondary influenza immunization due to broadening of the response by multiple HA
stimulations. (3) Efficient induction of antibodies against a desired epitope requires: (a] proliferation of a
favorable germline antibody and (b) an affinity maturation pathway to a desired final specificity. There are
preferred germline precursors and maturation pathways for antibodies targeting particular epitopes.
Hypotheses 1 and 2 will be tested by mapping the epitopes recognized by the repertoires of human subjects
with different exposure histories to influenza infection and/or immunization with adjuvanted or un-adjuvanted
vaccines. We will seek broadly neutralizing antibodies (those we want to elicit) to understand their germline
precursors and maturation pathways. We will also map the epitopes of the full range of antibodies that bind HA
to determine what the humoral immune system "sees." The insights obtained from this mapping will be used to
rationally design superior HA immunogens that will be optimized through an iterative cycle of antigen
engineering, mouse immunization, repertoire analysis, and antigen redesign. Antigen design techniques will
include selective epitope presentation, epitope masking, and germ-line antibody targetting followed by guided
affinity maturation. The principles of antigen design revealed by this work could be applied to protective
determinants of multiple pathogens for which vaccines are needed.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Manipulating immunodominance in influenza HA
-
批准号:8516983
-
项目类别:
-
资助金额:$52.92万
-
财政年份:2013
-
负责人:PHILIP R DORMITZER
-
依托单位:
Manipulating immunodominance in influenza HA
-
批准号:8377203
-
项目类别:
-
资助金额:$51.41万
-
财政年份:2012
-
负责人:PHILIP R DORMITZER
-
依托单位:
Manipulating immunodominance in influenza HA
-
批准号:8329262
-
项目类别:
-
资助金额:$55.48万
-
财政年份:2011
-
负责人:PHILIP R DORMITZER
-
依托单位:
Rotavirus VP4: Structure and function
-
批准号:7003807
-
项目类别:
-
资助金额:$31.64万
-
财政年份:2003
-
负责人:PHILIP R DORMITZER
-
依托单位:
Rotavirus VP4: Structure and function
-
批准号:6683722
-
项目类别:
-
资助金额:$18.8万
-
财政年份:2003
-
负责人:PHILIP R DORMITZER
-
依托单位:
Rotavirus VP4: Structure and function
-
批准号:6830198
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2003
-
负责人:PHILIP R DORMITZER
-
依托单位:
Rotavirus VP4: Structure and function
-
批准号:6756599
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2003
-
负责人:PHILIP R DORMITZER
-
依托单位:
STRUCTURAL BASIS FOR ROTAVIRUS ENTRY INTO CELLS
-
批准号:2886083
-
项目类别:
-
资助金额:$8.8万
-
财政年份:1998
-
负责人:PHILIP R DORMITZER
-
依托单位:
STRUCTURAL BASIS FOR ROTAVIRUS ENTRY INTO CELLS
-
批准号:2447964
-
项目类别:
-
资助金额:$8.8万
-
财政年份:1998
-
负责人:PHILIP R DORMITZER
-
依托单位:
STRUCTURAL BASIS FOR ROTAVIRUS ENTRY INTO CELLS
-
批准号:6168417
-
项目类别:
-
资助金额:$12.12万
-
财政年份:1998
-
负责人:PHILIP R DORMITZER
-
依托单位:
海外基金